

SeQuent Scientific to acquire Animal Health business of Lyka Exports

Mumbai, August 27, 2015: SeQuent Scientific Limited (SeQuent) and Lyka Labs Limited today announced that Alivira Animal Health Limited (Alivira), a subsidiary of SeQuent, and Lyka Exports Limited (Lyka), a subsidiary of Lyka Labs Limited, have entered into a definitive agreement under which Alivira will acquire the Animal Health Business of Lyka on a "going concern" basis.

The parties expect the transaction to close in next 6 weeks subject to customary closing conditions including shareholders' approval of Lyka. The proposed acquisition of Lyka's Animal Health Business includes all IPRs, Sales/ Marketing/Distribution network with related employees, contracts, assets and liabilities. The financial details of the transaction were not disclosed.

In FY15, Lyka's animal health business registered a topline of close to INR 235 million with EBITDA margins in the range of 12%. The business is growing by over 30% during the ongoing financial year (FY16)

Manish Gupta, Managing Director of SeQuent commented *"This acquisition augurs well for achieving Alivira's strategic objective of emerging a power house in the global Animal Healthcare space. The business being acquired will strengthen our portfolio in cattle and dairy segment and will complement our existing India formulations business. We are excited to welcome Lyka Animal Health's experienced business team to Alivira family.*

He further added *"Lyka's business is on a robust growth track with expanding margins and various strategic investments in place. The combined organization would have over 250+ strong field force coupled with a significantly wider product portfolio in the market. The acquisition would be immediately accretive for Sequent."*

N.I. Gandhi, the Chairman of Lyka stated *"The transaction, while strengthening our financials, also allows us to focus on creating value in the core pharma business. The proceeds will be predominately utilized to pare down debt. With SeQuent's focus and intent to develop a strong global Animal Health business in Alivira, the transaction offers great opportunities to the employees who are moving to the SeQuent family."*

DSK Legal acted as the legal advisor for the transaction on behalf of Alivira. Lyka was advised by **Ernst & Young**, as the M&A Advisor and **PDS Legal** as the Legal Advisor.

About SeQuent Scientific Limited / Alivira Animal Health Limited

SeQuent Scientific Limited (BSE-SEQUENT/512529) is an integrated pharmaceutical company with a global footprint, operating in the domains of Animal Health (API and formulation), Human Health (API) and Analytical Services. Headquartered in Mumbai, India, SeQuent has seven manufacturing facilities based in India and Turkey with approvals from global regulatory bodies including USFDA, EUGMP, WHO, TGA among others.

SeQuent 's Animal Health business is operated through its subsidiary Alivira Animal Health Ltd and SeQuent is poised to emerge as a global powerhouse in animal health business, built on a platform of superior quality and compliance.

About Lyka Labs Limited/ Lyka Exports Limited

Lyka Labs Limited (BSE-LYKALABS/500259: NSE-LYKALABS) is a leading pharmaceutical company with strong capabilities in Sterile Preparations and Dermatology. It has a wide portfolio of 20 Lyophilized Products and 50+ products in Dermatology. Its products are marketed across 46 markets globally. From its R&D Centre in Mumbai, Lyka is currently working on development of a wide range of New Formulations and New Drug Delivery System in its focus areas of Lyophilization and Dermatology and has a portfolio of over 20 products under development

For Queries, please contact

SeQuent Scientific Limited

Manish Gupta

Managing Director

Tel: +91 22 41114714

manish@sequent.in

Ankit Gupta

Christensen Investor Relations

Tel : +91 22 4215 0210

ankitgupta@christensenir.com

Registered Office

SeQuent Scientific Limited

301/A, 'Dosti Pinnacle',

Plot No.E7,Road No. 22,

Wagle Industrial Area, Thane (W),

Maharashtra, India

Corporate Information

CIN: L99999MH1985PLC036685

BSE Code:512529

ISIN:INE807F01019

REUTERS: SEQU.BO

Website: www.sequent.in

Lyka Labs Limited

Piyush Hindia

Company Secretary

Tel: +91 22 66112200

companysecretary@lylalabs.com

Registered Office

Lyka Labs Limited

4801/B & 4802/A G.I.D.C. Industrial

Estate, Ankleshwar – 393 002

Corporate Information

CIN: L24230GJ1976PLC008738

BSE Code: 500259

NSE Code: LYKALABS

Website: www.lylalabs.com

Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. Sequent Scientific Ltd. will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.

